Drug Candidate for Wilson Disease Meets Primary Endpoint in Phase III Trial | BioSpace
Alexion to Acquire Wilson Therapeutics for $855 Million - Equities News
Alexion Reports Positive Results from Phase 3 Trial of ALXN1840 in Wilson Disease - Global Genes
UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K ALEXION PHARMACEUTICALS, INC.
Alexion to acquire Wilson Therapeutics in $855m deal
Alexion bids $855m for rare disease biotech Wilson Therapeutics | pharmaphorum
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 1) (NASDAQ:ALXN) | Seeking Alpha
Alexion buys Swedish biotech for $855M to broaden rare disease pipeline
STAT on X: "Alexion Pharmaceuticals said it is buying Sweden's Wilson Therapeutics for $855 million, as the pace of deal-making in the biotech sector ticks higher. https://t.co/2dxJBMUvrX https://t.co/HOBUUk7HJK" / X
ex995wtxofferstatement
Alexion adds to pipeline rebuild with $855m Wilson buy - PMLiVE
Alexion's Wilson Therapeutics Deal Beats Its Synageva Distaster - Bloomberg
Alexion in €639m bid for Wilson Therapeutics AB - European Biotechnology
Alexion Acquires Swedish Treatment for Wilson's Disease
Alexion gets rare-disease-focused Wilson
Alexion refilling pipeline through potential $1.2bn Syntimmune buy - BioProcess InternationalBioProcess International
Alexion's Wilson Therapeutics Deal Beats Its Synageva Distaster - Bloomberg
Wilson Disease Association - Learn more about genetic testing and new treatments being developed for Wilson disease from this free webinar being held April 20th. Featured speaker Dr. Eve Roberts is on
Alexion Acquires Swedish Treatment for Wilson's Disease
ALEXION PHARMACEUTICALS, INC. - ALEXION'S NEXT CHAPTER Our Next Chapter & Advances shared mission of following the science and using innovative approaches to develop life-changing medicines for patientsStrengthens AstraZeneca's presence in immunology
Alexion gets rare-disease-focused Wilson
UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K ALEXION PHARMACEUTICALS, INC.
AstraZeneca dumps $855M, near-approval rare disease drug
